Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals (Nasdaq: KNSA) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 4:30 p.m. ET. A live webcast of the presentation can be accessed via the company’s Investors & Media section at kiniksa.com, with a replay available for 14 days post-conference.

Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet needs, featuring pipeline candidates like rilonacept and mavrilimumab.

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39^th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s product candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These pipeline assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

Every Second Counts!™ Kiniksa Investor and Media Contact Mark Ragosa (781) 430-8289 mragosa@kiniksa.com

FAQ

When will Kiniksa Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Kiniksa Pharmaceuticals will present on January 11, 2021, at 4:30 p.m. ET.

Where can I watch the Kiniksa Pharmaceuticals conference presentation?

The presentation will be available via webcast on Kiniksa's website at kiniksa.com.

How long will the Kiniksa Pharmaceuticals webcast be available?

The replay of the webcast will be available for 14 days following the conference.

What are the main therapeutic candidates developed by Kiniksa Pharmaceuticals?

Kiniksa's pipeline includes rilonacept, mavrilimumab, vixarelimab, and KPL-404.

What diseases does Kiniksa Pharmaceuticals focus on?

Kiniksa focuses on developing therapies for patients with debilitating diseases that have significant unmet medical needs.